PERSONAL Sign in with your SPIE account to access your personal subscriptions or to use specific features such as save to my library, sign up for alerts, save searches, etc.
Time-domain mesoscopic fluorescence molecular tomography (TD-MFMT) provides a unique window for non-invasively monitoring drug delivery efficacy parameters in targeted anticancer research, such as drug-receptor engagement and intra-tumoral heterogeneity. We investigate the potential of TD-MFMT for ex vivo assessment of Trastuzumab-HER2 target engagement and drug distribution in two types of breast and ovarian cancer tumor xenograft models (AU565 and SK-OV-3) via lifetime FRET technique. FRET fraction level and fluorescence drug distribution results reveal that drug accumulation within tumors cannot be automatically associated with targeted cellular drug delivery.
Shan Gao,Amit Verma,Margarida Barroso, andXavier Intes
"Ex vivo mesoscopic assessment of drug delivery and target engagement via lifetime FRET", Proc. SPIE 12357, Visualizing and Quantifying Drug Distribution in Tissue VII, 123570F (14 March 2023); https://doi.org/10.1117/12.2650632
ACCESS THE FULL ARTICLE
INSTITUTIONAL Select your institution to access the SPIE Digital Library.
PERSONAL Sign in with your SPIE account to access your personal subscriptions or to use specific features such as save to my library, sign up for alerts, save searches, etc.
The alert did not successfully save. Please try again later.
Shan Gao, Amit Verma, Margarida Barroso, Xavier Intes, "Ex vivo mesoscopic assessment of drug delivery and target engagement via lifetime FRET," Proc. SPIE 12357, Visualizing and Quantifying Drug Distribution in Tissue VII, 123570F (14 March 2023); https://doi.org/10.1117/12.2650632